期刊文献+

HIV-1与HIV-2交叉反应毒株的基因亚型分析 被引量:5

The Gene Subtype of Strain in the Cross Reaction of HIV-1 and HIV-2
下载PDF
导出
摘要 目的分析HIV-1+2蛋白印迹试验中HIV-1确证阳性同时出现HIV-2带型样本的基因亚型。方法将HIV-1+2确证试验中同时出现HIV-2带型的样本,通过基因诊断确认是否为HIV-2共感染;同时扩增HIV-1 gag,env基因段,通过测序和系统进化树的构建,分析具有HIV-2带型的HIV-1毒株的基因亚型。结果在34份出现HIV-2带型的标本中,基因诊断发现均为交叉反应,并非HIV-1和HIV-2共感染。出现交叉反应的毒株中以AE亚型为主,占73.5%(25/34),BC重组和B亚型分别占17.7%(6/34)和8.8%(3/34)。结论HIV-1+2蛋白确证试验中HIV-1确证阳性,同时出现HIV-2带型的阳性样本,并非HIV-1和HIV-2共感染,而是交叉反应。出现交叉反应的HIV-1毒株以AE亚型为主。 Objective To study the gene subtype of strain in the cross reaction of HIV - 1 and HIV - 2. Methods Col- lected the HIV - 1 + 2 confirmatory test samples with HIV - 2 band, to confirm if HIV - 2 infection through the gene diagnostic. Amplificated HIV - 1 env and gag gene by PCR;Studied the HIV - 1 gene subtype with HIV -2 cross reaction by Sequencing and polygenetic analysis. Results These samples with HIV - 1 and HIV - 2 band were not HIV - 1 and HIV - 2 co - infection but cross reaction with HIV - 2, Studied the env and gag gene of HIV - 1 with HIV - 2 cross reaction found that AE subtype was 73. 5% (25/34) ; BC subtype was 17.7 % (6/34) ; B subtype was 8.8% (3/34) ; had no other subtype was found in these samples. Conclusion Most HIV - 1 + 2 confirmatory test samples with HIV - 2 bands were not HIV - 1 and HIV - 2 co - infection, but HIV - 1 and HIV - 2 cross reaction. The AE subtype of HIV - 1 was mainly with cross reaction in this research.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2008年第4期198-200,共3页 The Chinese Journal of Dermatovenereology
关键词 交叉反应 HIV-1 HIV-2 基因亚型 聚合酶链反应 Cross Reaction HIV - 1, HIV - 2 Gene Subtype Polymerase Chain Reaction(PCR)
  • 相关文献

参考文献9

二级参考文献40

  • 1Esteves A, Parreira R, Piedade J, et al. Genetic characterization of HIV type 1 and type 2 from Bissau, Guinea-Bissau ( West Africa).Virus Res, 2000, 68: 51-61.
  • 2Kong LI, Lee SW, Kappes JC, et al. West African HIV-2-related human retrovirus with attenuated cytopathicity. Science,1988, 240:1525-1529.
  • 3Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol, 1994, 68 : 7433-7447.
  • 4Damond F, Apetrei C, Robertson DL, et al. Variability of human immunodeficiency virus type 2 ( hiv-2 ) infecting patients living in France. Virology, 2001, 280: 19-30.
  • 5Kannangai R, Ramalingam S, Prakash KJ, et al. Molecular confirmation of human immunodeflciency vires ( HIV ) type 2 in HIVseropositive subjects in south India. Clin Diagn Lab Immunol, 2000,7:987-989.
  • 6[6]Robertson DL,Sharp PM,McCutchan FE,et al.Recombination in HIV-1[J].Nature,1995,374:124-126.
  • 7[7]Cheng H,ZhangJ,CapizziJ,etal.HIV-1 EsubtypeinYunnan[J].Lancet.1994.344:953-954.
  • 8[8]Mccutchan FE,Artenstein AW,Sanders-buell E,et al.Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa[J].J Viro,1996,70(6):3331-3338.
  • 9[9]Lou CC,Tian C,Hu D,et al.HIV-1 subtype C in China[J].Lancet 1995,345:1051-1052.
  • 10[10]SuL,Graf M,ZhangYZH,etal.Ciaracterizationofavirtually fulllength human immunodeficiency virus type 1 genome of a prevalent intersubtype(C/B′) recombinant strain in China[J].J Viro,2000,74(23):11367-11376.

共引文献32

同被引文献43

  • 1詹军,潘国新,陆海霞,夏宁基.宁夏首例HIV-1/2型混合感染者的实验室诊断[J].宁夏医学杂志,2005,27(11):772-773. 被引量:4
  • 2高凯,李燕,梁彩云,徐慧芳,顾菁,李泽荣,赵宇腾,张周斌.广州市发现首例HIV-1/HIV-2混合感染[J].华南预防医学,2006,32(1):17-19. 被引量:5
  • 3邱茂锋,邢文革,蒋岩,裴丽健,闫红梅,秦淑文,张桂云.我国人类免疫缺陷病毒2型感染的初步回顾性血清学调查[J].现代预防医学,2007,34(12):2215-2216. 被引量:3
  • 4梁跃波,李亚平,候中生,刘中华,杨学兵,王春梅,唐晓萍,邓荣,刘义夫,李洪,王志坚.云南边境地区HIV-1型和HIV-2型混合感染的流行病学分析[J].中国国境卫生检疫杂志,2007,30(6):331-333. 被引量:6
  • 5龙亚秋.艾滋病治疗药物的研究进展[J].药学服务与研究,2007,7(6):401-407. 被引量:10
  • 6Kunal Roy, J. Thomas Leonard. QSAR modeling of HIV- 1 reverse transcriptase inhibitor 2-amino-6-arylsulfonyl benzonitriles and congeners using molecular connectivity and E-state parameters [J]. Bioorganic & Medicinal Chemistry, 2004,12(4) : 745-754.
  • 7Ge Meng, Yang Liu, Aqun Zheng, et al. Design and syn- thesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors[J]. European Journal of Medicinal Chemistry, 2014,82 : 600-611.
  • 8Richard D. Cramer. Topomer CoMFA: A design methodol- ogy for rapid lead optimization[J]. Journal of Medicinal Chemistry,2003,46(3) :374-388.
  • 9Richard D. Cramer,Phillip Cruz,Gunther Stahl,et al. Vir- tual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using To- pomer CoMFA[J]. Journal of Chemical Information and Modeling,2008,48(11) :2 180-2 195.
  • 10H. Van De Waterbeemd. Chemometric methods in drug design[M]. VCH : Weinheim, 1995.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部